NME1 and neoplasm: We found that NM23-positive NSCLC patients had a higher 5-year OS rate than NM23-negative NSCLC patients, and the 5-year tumor metastasis rate in NM23-positive NSCLC patients was observed at a lower level than in NM23-negative NSCLC patients.